Landscapes / Companies
Jubilant Therapeutics Inc. not checked
FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
2 in Phase 2
Drugs
2
in active trials
Trials
2 active
3 since 2021
Drugs2
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
— |
Phase 1/2 | 31 Mar 2030Phase 1/2 trial completes | |||
| Next date | 31 Mar 2030 · Phase 1/2 trial completes | ||||
| Also tested for | Brain Metastases From Solid Tumors, Leptomeningeal Disease and 5 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Jan 2031Phase 1/2 trial completes | |||
| Next date | 30 Jan 2031 · Phase 1/2 trial completes | ||||
| Also tested for | Essential Thrombocythemia (ET), Polycythemia Vera | ||||
| Open drug page | |||||
About
- SEC filings
- None: it does not file with the US SEC
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021